Zak Zimmerman, PhD, is the CEO and co-founder of Forge Therapeutics. Zak has forged a successful path from bench scientist to industry to entrepreneur, marking a unique career trajectory that has successfully driven company growth for several biotechnology companies, both private and public, spanning more than 15 years. In 2015, Zak co-founded Forge Therapeutics to tackle the most serious unmet medical needs with novel chemistry. Initially, Forge chose to tackle a global health problem that industry and pharma had turned away from – antibiotic resistance. As part of these risk-taking efforts, Forge raised a $17.5 million Series A, received $19.9 million in non-dilutive support from CARB-X, and formed a novel antibiotic alliance with Swiss pharma Basilea with payments up to $167 million per target.